Jia, C., Zhang, S., Wang, J., Feng, B., Shi, F., Wang, M., Li, S., Xu, H., Wang, M. (2025). Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China. Scientific Reports. https://doi.org/10.1038/s41598-025-97504-3